MAP3K5 and glioma: In glioma, gefitinib promotes ROS production via NOX2 and NOX4, triggering endoplasmic reticulum stress and activating the apoptosis signal-regulating kinase 1/c-Jun N-terminal kinase/Noxa (Ask1/JNK/Noxa) pathway, which results in caspase-dependent apoptosis [14].